Targeting fatty acid metabolism in heart failure: Is it a suitable therapeutic approach?

Drug Discovery Today

Volumn 21, Issue 6, 2016, Pages 1003-1008

  Arumugam, Somasundaram ^a   Sreedhar, Remya ^a   Thandavarayan, Rajarajan A ^b   Karuppagounder, Vengadeshprabhu ^a   Watanabe, Kenichi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; FATTY ACID;

CARBOHYDRATE METABOLISM; DIABETES MELLITUS; ENERGY METABOLISM; ENERGY YIELD; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HEART FAILURE; HEART MUSCLE METABOLISM; HEMODYNAMIC STRESS; HUMAN; INSULIN RESISTANCE; NONHUMAN; OBESITY; REVIEW; STRESS; ANIMAL; CARDIAC MUSCLE; METABOLISM; PHYSIOLOGICAL STRESS;

ANIMALS; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; FATTY ACIDS; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MYOCARDIUM; OBESITY; STRESS, PHYSIOLOGICAL;

EID: 84959470387     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.02.010     Document Type: Review

References (51)

1. T. Nagoshi, and et al. Optimization of cardiac metabolism in heart failure Curr. Pharm. Des. 17 2011 3846 3853
2. C. Depre, and et al. Glucose for the heart Circulation 99 1999 578 588
3. S.K. Banerjee, and et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states Cardiovasc. Res. 84 2009 111 118
4. J.M. Berg, and et al. Glycolysis is an energy-conversion pathway in many organisms J.M. Berg, Biochemistry 5th edn 2002 W.H. Freeman & Co.
5. Y. Wei, and et al. Multifaceted roles of miR-1s in repressing the fetal gene program in the heart Cell Res. 24 2014 278 292
6. S. Violante, and et al. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines FASEB J. 27 2013 2039 2044
7. S.J. Wakil, and L.A. Abu-Elheiga Fatty acid metabolism: target for metabolic syndrome J. Lipid Res. 50 2009 S138 S143
8. J. Plutzky The PPAR-RXR transcriptional complex in the vasculature: energy in the balance Circ. Res. 108 2011 1002 1016
9. B.N. Finck, and D.P. Kelly Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease Circulation 115 2007 2540 2548
10. Y. Zhang, and et al. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR Genes Dev. 18 2004 157 169
11. V. Lionetti, and et al. Modulating fatty acid oxidation in heart failure Cardiovasc. Res. 90 2011 202 209
12. S. Sankaralingam, and G.D. Lopaschuk Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure Pulm. Circ. 5 2015 15 28
13. M.P. Chandler, and et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation Am. J. Physiol. Heart Circ. Physiol. 287 2004 H1538 H1543
14. J.C. Schisler, and et al. Cardiac energy dependence on glucose increases metabolites related to glutathione and activates metabolic genes controlled by mechanistic target of rapamycin J. Am. Heart Assoc. 4 2015 e001136
15. A. Akki, and et al. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation Mol. Cell. Biochem. 311 2008 215 224
16. A.R. Vest Incretin-related drug therapy in heart failure Curr. Heart Fail. Rep. 12 2015 24 32
17. C. Riehle, and et al. PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy Circ. Res. 109 2011 783 793
18. A. Nabeebaccus, and et al. Cardiac-targeted NADPH oxidase 4 in the adaptive cardiac remodelling of the murine heart Lancet 385 Suppl. 1 2015 S73
19. R.R. Russell 3rd, and et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury J. Clin. Invest. 114 2004 495 503
20. M.M. Sung, and et al. AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism Cardiovasc. Res. 107 2015 235 245
21. K. Aravindhan, and et al. Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart PLoS ONE 10 2015 e0130894
22. D. An, and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am. J. Physiol. Heart Circ. Physiol. 291 2006 H1489 H1506
23. M. Bayeva, and et al. Taking diabetes to heart-deregulation of myocardial lipid metabolism in diabetic cardiomyopathy J. Am. Heart Assoc. 2 2013 e000433
24. O. Ilkun, and S. Boudina Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies Curr. Pharm. Des. 19 2013 4806 4817
25. E.D. Abel Free fatty acid oxidation in insulin resistance and obesity Heart Metab. 48 2010 5 10
26. H. Gao, and et al. Downregulation of adipose triglyceride lipase promotes cardiomyocyte hypertrophy by triggering the accumulation of ceramides Arch. Biochem. Biophys. 565 2015 76 88
27. J.E. Rodriguez, and et al. The ubiquitin ligase MuRF1 regulates PPARalpha activity in the heart by enhancing nuclear export via monoubiquitination Mol. Cell. Endocrinol. 413 2015 36 48
28. K. Watanabe, and et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity J. Biol. Chem. 275 2000 22293 22299
29. A.L. Birkenfeld, and et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans J. Clin. Endocrinol. Metab. 90 2005 3622 3628
30. W.A. Baseler, and et al. Proteomic alterations of distinct mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import dysfunction Am. J. Physiol. Regul. Integr. Comp. Physiol. 300 2011 R186 R200
31. A.T. Akhmedov, and et al. Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart Heart Fail. Rev. 20 2015 227 249
32. A.J. Murray, and et al. Uncoupling proteins in human heart Lancet 364 2004 1786 1788
33. G. Aubert, and et al. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart Biochim. Biophys. Acta 1833 2013 840 847
34. A.R. Wende, and et al. Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes Mol. Cell. Biol. 35 2015 831 846
35. S.W. Schaffer, and et al. Impaired energy metabolism of the taurine-deficient heart Amino Acids 48 2015 549 558
36. A. Kadkhodayan, and et al. A 'PET' area of interest: myocardial metabolism in human systolic heart failure Heart Fail. Rev. 18 2013 567 574
37. J.R. Ussher, and et al. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice Can. J. Cardiol. 30 2014 940 944
38. T. Senturk, and et al. Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury Atherosclerosis 237 2014 760 766
39. G. Fragasso, and et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study Int. J. Cardiol. 163 2013 320 325
40. E.N. Dedkova, and et al. Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure J. Mol. Cell. Cardiol. 59 2013 41 54
41. J.D. Horowitz, and et al. Modulation of myocardial metabolism: an emerging therapeutic principle Curr. Opin. Cardiol. 25 2010 329 334
42. H. Nakajima, and et al. Endothelial lipase modulates pressure overload-induced heart failure through alternative pathway for fatty acid uptake Hypertension 61 2013 1002 1007
43. A. Akki, and A.M. Seymour Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy Cardiovasc. Res. 81 2009 610 617
44. A.J. Chicco, and et al. Linoleate-rich high-fat diet decreases mortality in hypertensive heart failure rats compared with lard and low-fat diets Hypertension 52 2008 549 555
45. G.C. Sparagna, and E.J. Lesnefsky Cardiolipin remodeling in the heart J. Cardiovasc. Pharmacol. 53 2009 290 301
46. R. Lahey, and et al. Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride Circulation 130 2014 1790 1799
47. R. Harmancey, and et al. Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart FASEB J. 27 2013 3966 3978
48. T.T. Yamanushi, and et al. Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats J. Nutr. 144 2014 467 474
49. Y. Fang, and et al. Reduced cardiac remodelling and prevention of glutathione deficiency after omega-3 supplementation in chronic heart failure Fundam. Clin. Pharmacol. 25 2011 323 332
50. L.S. Szczepaniak, and et al. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America Circ. Res. 101 2007 759 767
51. H. Ashrafian, and et al. Metabolic mechanisms in heart failure Circulation 116 2007 434 448